Year: 2015
Type: article
Abstract: Meeting abstracts Immunotherapy has become one of the most profound advances in the treatment of solid tumors. Unlike the prior targeted therapies such as kinase inhibitors, there are no clear mutations or definitive biomarkers of which patients are likely to respond. It is well documented that
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2213998802